Myriad Genetics logo
Myriad Genetics MYGN
$ 3.16 1.92%
report update icon

Quarterly report 2026-Q2
added 07-31-2026

Myriad Genetics Financial Statements 2025-2008 | MYGN

Annual Financial Statements Myriad Genetics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

409 M 973 M 1.8 B 1.74 B 2.21 B 1.49 B 2 B 2.97 B 1.62 B 2.17 B 2.4 B 2.78 B 2.43 B 2.19 B 1.91 B 1.72 B 3.45 B -

Shares

92.6 M 90.6 M 82.8 M 80.6 M 80 M 75.4 M 73.5 M 69.4 M 68.3 M 70 M 71.3 M 75.7 M 80.9 M 84.6 M 89.8 M 96.3 M 93.5 M -

Historical Prices

4.42 10.7 21.8 21.6 27.6 19.8 27.2 29.1 34.4 16.7 43.2 34.1 21 27.2 20.9 17.8 36.9 24.6

Net Income

-366 M -127 M -263 M -112 M -27.2 M -53.1 M 4.6 M 131 M 21.8 M 125 M 80.2 M 176 M 147 M 112 M 101 M 152 M 84.6 M -

Revenue

824 M 838 M 753 M 678 M 691 M 300 M 851 M 773 M 771 M 754 M 723 M 778 M 613 M 496 M 402 M 363 M 327 M -

Cost of Revenue

248 M 252 M 236 M 202 M - - - - 145 M 133 M 133 M 96.1 M 64.4 M 51.5 M 45.6 M 44.3 M 43.3 M -

Gross Profit

577 M 585 M 517 M 476 M - - - 595 M 600 M 596 M 576 M 669 M 534 M 431 M 355 M - - -

Operating Income

-387 M -124 M -257 M -141 M -190 M -87.8 M 7.6 M 122 M 44 M 153 M 134 M 274 M 228 M 180 M 158 M 135 M 126 M -

Interest Expense

800 K 1.1 M 2.9 M 3.2 M 6.6 M 5.8 M 12 M 3.2 M 6 M 300 K 200 K -2 M -200 K -407 K 1.87 M - - -

EBITDA

-334 M -62.3 M -196 M -87.9 M -128 M -52 M 80.6 M 112 M 97.7 M 194 M 159 M 288 M 237 M 189 M 165 M 142 M 136 M -

Operating Expenses

964 M 709 M 774 M 617 M - - - 538 M 551 M 430 M 442 M 395 M 306 M 251 M 198 M - - -

General and Administrative Expenses

257 M 276 M 284 M 248 M 538 M 260 M 556 M 467 M 476 M 359 M 366 M 327 M 252 M 208 M 170 M 161 M 139 M -

All numbers in USD currency

Quarterly Income Statement Myriad Genetics

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

94.8 M 93.7 M 93.1 M 92.5 M 91.4 M 91.3 M 90.9 M 90.6 M 89.9 M 89.9 M 81.9 M 81.7 M 81.3 M 81.2 M 80.7 M 80.4 M 80.1 M 80 M 78.8 M 77.2 M 76 M 75.4 M 74.7 M 74.6 M 74.7 M 74.4 M 73.7 M 74.4 M 73.7 M 74.2 M 73 M 74.2 M 73 M 69.3 M 68.6 M 69.3 M 68.6 M 68.2 M 68.8 M 68.2 M 68.8 M 70.5 M 68.7 M 70.5 M 68.7 M 72.5 M 72.8 M 72.5 M 72.8 M 75.1 M 79.6 M 75.1 M 79.6 M 81.7 M 81.6 M 81.7 M 81.6 M 84.5 M 85.2 M 84.5 M 85.2 M

Net Income

-43.2 M -34.1 M -27.4 M -330 M -100 K - -22.1 M -36.7 M -26 M - -61.3 M -116 M -54.7 M - -35.1 M -14.1 M -20.5 M - 24.6 M -4.7 M -39.5 M -37.9 M -15.2 M -55.4 M -15.2 M -8.3 M -8.3 M -8.3 M -20.6 M 2.6 M 2.6 M 2.6 M -700 K 30.9 M 78.8 M 32.1 M 81.1 M 6.1 M -700 K 5.9 M -1.2 M 37.1 M 30.3 M 30.3 M 26.6 M 24 M 16 M 24 M 16 M 50.4 M 55.5 M 50.4 M 55.5 M 35 M 30.1 M 35 M 30.1 M 28.3 M 25.1 M 28.3 M 25.1 M

Revenue

191 M 200 M 206 M 213 M 196 M - 213 M 212 M 202 M - 192 M 184 M 181 M - 156 M 179 M 165 M - 167 M 189 M 173 M 155 M 145 M 93.2 M 145 M 195 M 186 M 195 M 186 M 217 M 202 M 217 M 194 M 194 M 190 M 384 M 197 M 196 M 178 M 196 M 178 M 193 M 184 M 193 M 184 M 184 M 169 M 184 M 169 M 204 M 202 M 204 M 202 M 149 M 133 M 149 M 133 M 123 M 110 M 123 M 110 M

Cost of Revenue

63.7 M 62.8 M 61.9 M 61.3 M 61.7 M - 63.5 M 64.4 M 64.6 M - 57.6 M 57.8 M 59.2 M - 50.4 M 49.7 M 48 M - - - - - - - - - - - - - - - 36.8 M 37.7 M 36.2 M 73.9 M 37.9 M 37.4 M 34.3 M 37.4 M 34.3 M 34.1 M 30.9 M 34.1 M 30.9 M 35.1 M 32.8 M 35 M 32.8 M 22.8 M 21.4 M 22.8 M 21.4 M 15.6 M 13.9 M 15.6 M 13.9 M 12.8 M 11.3 M 12.8 M 11.3 M

Gross Profit

127 M 138 M 144 M 152 M 134 M - 150 M 147 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-38.9 M -30.7 M -23.3 M -329 M -29 M - -20 M -36.5 M -27.9 M - -60.1 M -114 M -52.2 M - -45 M -17.8 M -25.6 M - -79.9 M -20.8 M -46.7 M -48.2 M -39.6 M -68.3 M -39.6 M -8.8 M -20.9 M -8.8 M -20.9 M 6.1 M 1.2 M 6.1 M 1.2 M 6.3 M 84 M 4.4 M 87.4 M 17.2 M 7.1 M 13.2 M 6.2 M 45.2 M 43.3 M 45.2 M 43.3 M 36.3 M 25.9 M 36.3 M 25.9 M 83 M 82.9 M 83 M 82.9 M 55.6 M 48.6 M 55.6 M 48.6 M 45.5 M 41.5 M 45.5 M 41.5 M

Interest Expense

- - 400 K -100 K 100 K - -800 K -300 K 500 K - -700 K -2.4 M 500 K - 800 K 600 K 900 K - 1.1 M 2 M 3 M 2.9 M 2.9 M 3.1 M 2.9 M 2.5 M 2.9 M 2.5 M 2.9 M 3.4 M 2.2 M 3.4 M 2.2 M 700 K 900 K 700 K 900 K 2.6 M 700 K 2.6 M -2.5 M 100 K 100 K -300 K 100 K 1.5 M -100 K 1.51 M -98 K -185 K -439 K -185 K 923 K 14 K 1.24 M - - - - - 488 K

EBITDA

-13.9 M -18.2 M -18.5 M -324 M -14.6 M - -15.2 M -31.9 M -12.2 M - -56.7 M -111 M -32.8 M - -42.1 M -15 M -12.6 M - -30.4 M -3.9 M -28.3 M -48.2 M -21.9 M -50.6 M -21.9 M 9.4 M -2.7 M 27.6 M -2.7 M 24.1 M 19.5 M 24.1 M 19.5 M 19.4 M 97.2 M 17.5 M 101 M 30.1 M 16.3 M 26.2 M 15.4 M 52 M 50.1 M 52 M 50.1 M 42.3 M 31.9 M 42.4 M 31.9 M 85.4 M 85.3 M 85.4 M 85.3 M 57.8 M 50.8 M 60 M 48.9 M 45.7 M 43.6 M 49.9 M 43.6 M

Operating Expenses

166 M 168 M 167 M 481 M 163 M - 170 M 184 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

57.8 M 62.2 M 67.9 M 66.8 M 66.5 M - 69.2 M 72.1 M 141 M - 136 M 141 M 152 M - 130 M 127 M 111 M - 181 M 135 M 146 M 133 M 124 M 107 M 124 M 134 M 136 M 136 M 136 M 135 M 130 M 135 M 130 M 107 M 107 M 115 M 115 M 120 M 112 M 120 M 112 M 90.8 M 86.5 M 90.8 M 86.5 M 92.7 M 85.4 M 92.7 M 85.4 M 77.8 M 77.3 M 77.8 M 77.3 M 59.6 M 56.1 M 59.6 M 56.1 M 51 M 46.1 M 51 M 46.1 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Myriad Genetics MYGN
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Myriad Genetics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Biomerica Biomerica
BMRA
$ 2.14 1.9 % $ 4.92 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.17 0.88 % $ 6.37 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Co-Diagnostics Co-Diagnostics
CODX
$ 1.21 0.79 % $ 1.61 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 14.3 0.7 % $ 486 M israelIsrael
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 242.76 0.02 % $ 26.9 B usaUSA
Celcuity Celcuity
CELC
$ 88.44 3.05 % $ 4.14 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Charles River Laboratories International Charles River Laboratories International
CRL
$ 291.5 0.16 % $ 14.4 B usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 6.77 1.18 % $ 27 M israelIsrael
DexCom DexCom
DXCM
$ 90.82 1.71 % $ 35.4 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 398.58 0.64 % $ 28.8 B schweizSchweiz
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 5.01 4.53 % $ 3.94 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 18.05 7.31 % $ 2.31 B usaUSA
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
National Research Corporation National Research Corporation
NRC
$ 21.85 0.27 % $ 489 M usaUSA
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.48 1.11 % $ 113 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.4 0.32 % $ 420 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 170.02 0.18 % $ 13.3 B irlandaIrlanda
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.45 2.11 % $ 6.41 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 261.75 0.05 % $ 45 B usaUSA
Surmodics Surmodics
SRDX
- - $ 608 M usaUSA